TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06094010: A Phase IIIb Multicenter, Single-arm, Open-label Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Patients With Influenza and Transmission of Influenza to Household Contacts

Sponsor: Hoffmann-La Roche · Phase: PHASE3 · Area: INFECTIOUS_VACCINE · Target Enrollment: 1100 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$8,558,340

Rescue Site Savings

+$5,635,980

Unlock Full NCT06094010 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06094010 Rescue Dossier →